What is the cost of Lymphoma treatment in China?

Starting from $1,500 up to $2,500, depending on disease severity and treatment protocol. Contact our team for a personalized quote.

How soon can I start Lymphoma treatment in China?

5-7 days. Urgent cases can often be accommodated sooner. We prioritize international patient scheduling.

How long does Lymphoma treatment take?

Typical hospital stay is IV every 21 days × 6. Total time in China depends on recovery phase and follow-up needs.

What is the recovery time for Lymphoma treatment?

Recovery typically takes Outpatient. Our multidisciplinary team provides comprehensive post-operative care and 12-month remote follow-up.

How do I start Lymphoma treatment with SSAnkang?

Simply submit your medical records via our website, WhatsApp, or email. Our specialist team will evaluate your case within 24-48 hours and provide a personalized treatment plan and cost estimate.

Oncology & Cancer Care

Lymphoma

China leads global CAR-T research with 700+ active trials. Domestic CD19 and BCMA CAR-T products approved at fraction of Western cost.

Treatment Options

Recommended Centers

$1,500

Starting From

7-21 days

Typical Wait

Treatment Plans for Lymphoma

Compare evidence-based options at top Chinese hospitals — transparent pricing, typical wait, and recovery time.

Flagship Plan

R-CHOP Chemoimmunotherapy

6-cycle rituximab + CHOP for diffuse large B-cell lymphoma.

Wait Time

5-7 days

Hospital Stay

IV every 21 days × 6

Recovery

Outpatient

Estimated Price

Approx. $1,800/cycle

View Detailed Introduction — Procedure, Price Comparison & More

Price Comparison: China vs. USA

🇨🇳 China

$1,500

🇺🇸 USA

$6,250+

Save up to $4,750 per treatment

Procedure Steps

Pre-op: excisional biopsy + PET-CT staging + bone marrow

PICC or port-a-cath insertion

Day 1: rituximab 375mg/m² IV (first dose 6-8 hours, subsequent 90 min)

Day 1: cyclophosphamide + doxorubicin + vincristine IV

Day 1-5: prednisone 100mg PO daily

Repeat every 21 days × 6 cycles

Interim PET-CT after 3 cycles (Deauville score)

End-of-treatment PET-CT → complete metabolic response assessment

What is R-CHOP?

The gold-standard first-line chemoimmunotherapy for diffuse large B-cell lymphoma (DLBCL), combining the anti-CD20 antibody rituximab with CHOP chemotherapy. Cures 60-70% of patients.

Why China?

Rituximab biosimilar: Domestic rituximab at 1/4 imported cost
Cost per cycle: $1,500-$2,500 vs. $8,000-$15,000 in the US
Expert hematology: Ruijin, PUMC, and Tianjin Cancer among Asia's top lymphoma centers

Who is a candidate?

Newly diagnosed CD20+ DLBCL
ECOG 0-2
Adequate cardiac function (LVEF ≥50%)

Outcomes

Complete response rate: 75-80%. 5-year overall survival: 60-70%. IPI score guides prognosis stratification.

Book Free Consultation WhatsApp

CD19 CAR-T Cell Therapy

Autologous CAR-T (relmacabtagene/lis-cel) for relapsed/refractory B-cell lymphoma.

Wait Time

21-30 days

Hospital Stay

3-4 weeks inpatient

Recovery

3-6 months

Estimated Price

Approx. $130,000

View Detailed Introduction — Procedure, Price Comparison & More

Price Comparison: China vs. USA

🇨🇳 China

$110,000

🇺🇸 USA

$450,000+

Save up to $340,000 per treatment

Procedure Steps

Eligibility: relapsed/refractory B-cell lymphoma after ≥2 lines

Leukapheresis: collect patient T cells (4-6 hours)

CAR-T manufacturing: gene transduction + expansion (14-21 days)

Bridging therapy during manufacturing if needed

Lymphodepleting chemotherapy: fludarabine + cyclophosphamide × 3 days

CAR-T cell infusion: single IV dose (30-60 minutes)

CRS monitoring in ICU: tocilizumab ready

ICANS monitoring: neurological checks every 4 hours × 7 days

What is CD19 CAR-T?

Chimeric Antigen Receptor T-cell therapy genetically engineers your own T cells to recognize and destroy CD19-positive lymphoma cells. It represents a potentially curative option for patients who have failed conventional chemotherapy.

Why China?

Domestic products: Relmacabtagene (relma-cel) and equecabtagene (equ-cel) NMPA-approved
Cost: $110,000-$180,000 vs. $370,000-$475,000 in the US (Yescarta/Kymriah)
700+ trials: China leads global CAR-T clinical research volume
Novel targets: Access to CD19/CD22 dual-target and CD20 CAR-T trials

Who is a candidate?

Relapsed/refractory DLBCL after ≥2 lines of therapy
Relapsed after auto-HSCT or ineligible for transplant
Adequate organ function

Outcomes

Overall response rate: 70-80%. Complete response: 50-60%. Estimated 2-year PFS: 40-50%. CRS rate: 80% (mostly grade 1-2).

Book Free Consultation WhatsApp

Prices are indicative ranges in USD based on partner hospital published rates. Final quote depends on your medical records and selected hospital — request a free personalized estimate.

Why China for Lymphoma

Domestic CAR-T (axicabtagene biosimilar) at 1/4 Western cost; world-class allo-HSCT programs.

Recommended Hospitals for Lymphoma

Hand-picked by case volume, outcomes, and international patient experience.

Beijing

About Lymphoma

Common Symptoms

Painless lymphadenopathy
Night sweats
Fever
Weight loss (B-symptoms)
Fatigue

Common Causes

EBV infection
HIV/HCV
Immunosuppression
Genetic predisposition

Diagnostic Methods

Excisional lymph node biopsy
PET-CT staging
Bone marrow biopsy
Flow cytometry

Related Conditions

Free Consultation

Get a personalized Lymphoma treatment plan

Specialist review of your records within 24h
Matched to top hospitals & doctors
Transparent quote — no hidden fees
Visa, travel, and translation support

— or contact us directly —

WhatsApp +86 19392777259 Email Us

Confidential · No obligation · GDPR compliant

Lymphoma

Treatment Plans for Lymphoma

R-CHOP Chemoimmunotherapy

What is R-CHOP?

Why China?

Who is a candidate?

Outcomes

CD19 CAR-T Cell Therapy

What is CD19 CAR-T?

Why China?

Who is a candidate?

Outcomes

Why China for Lymphoma

Recommended Hospitals for Lymphoma

Peking Union Medical College Hospital

Tianjin Medical University Cancer Hospital

Sun Yat-Sen University Cancer Center

Ruijin Hospital, Shanghai Jiao Tong University

Peking University Cancer Hospital

Shanghai Cancer Center, Fudan University

Sichuan Cancer Hospital and Institute

About Lymphoma

Related Conditions